Andrés Felipe Bedoya López

Mr. Andrés Felipe Bedoya López


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 November 2025 in Research Square
Verified
Preprint
Open access
PDF file
DMDiego M. Marzese
Diego M. Marzese
ALAndrés Felipe Bedoya López
Andrés Felipe Bedoya López
JOJavier Orozco
Javier Orozco
MEMiquel Ensenyat-Mendez
Miquel Ensenyat-Mendez
BVBetsy Valdez
Betsy Valdez
PAPere Llinàs Arias
Pere Llinàs Arias
Triple-negative breast cancer (TNBC) is a major cause of cancer mortality, with distant metastases presenting a significant clinical challenge. While epigenetic mechanisms like DNA methylation are known to influence TNBC progression, their specific role in driving metastasis remains underexplored. To address this gap, we performed comprehensive multi-omics analysis, integrating epigenomic and transcriptomic profiles from TNBC xenograft models and patient cohorts. Genome-wide DNA methylation profiling of primary tumors, lymph nodes, and lung metastases from xenografts revealed pronounced global hypomethylation in lung lesions, consistent with findings from the clinical cohort. Promoter-methylation changes were enriched in pathways linked to invasion and proliferation, and transcriptomic integration identified 22 epigenetically regulated genes. Among these, elevated AK1 , SLC2A5 , TPI1 , and ZBTB17 expression correlated with a higher risk of lung dissemination. These findings highlight altered DNA methylation as a driver of TNBC lung colonization and identify candidate prognostic markers, emphasizing the importance of epigenetic reprogramming in organ-specific lung metastases.

21 July 2026 in Communications Biology
Verified
Journal Article
Open access
PDF file
ALAndrés Felipe Bedoya López
Andrés Felipe Bedoya López
SÍSandra Íñiguez-Muñoz
Sandra Íñiguez-Muñoz
JOJavier I. J. Orozco
Javier I. J. Orozco
MEMiquel Ensenyat-Méndez
Miquel Ensenyat-Méndez
BVBetsy J. Valdez
Betsy J. Valdez
DMDiego M. Marzese
Diego M. Marzese
Triple-negative breast cancer (TNBC) is a major cause of cancer mortality, with distant metastases, particularly to the lungs, presenting a significant clinical challenge. While epigenetic mechanisms like DNA methylation (DNAm) are known to influence TNBC progression, their association with lung metastasis remains underexplored. To address this gap, we analyze epigenomic and transcriptomic profiles from TNBC cells, xenograft models, and patient cohorts. DNAm profiling of primary tumors, lymph nodes, and lung metastases in our xenograft model reveals significant genome-wide hypomethylation in lung lesions, consistent with findings on patient samples from the AURORA US cohort. Promoter-methylation changes are enriched in pathways linked to invasion and proliferation, and transcriptomic integration identifies 22 regulated genes, with outcome effects varying according to the histone chromatin context. In vitro demethylation in TNBC cells partially recapitulates the expression changes of several candidate genes. Beyond promoters, enhancer elements are also dysregulated in lung metastases, potentially affecting the expression of their associated genes. Among others, elevated AK1, TPI1, and ENO1 expression correlates with a higher risk of lung dissemination in primary TNBC tumors. These findings highlight DNAm alterations associated with TNBC lung colonization and identify candidate prognostic markers, emphasizing DNAm reprogramming as a feature of breast-to-lung-metastatic progression.

Verified
Journal Article
Open access
PDF file
SISandra Iñiguez-Muñoz
Sandra Iñiguez-Muñoz
ALAndrés Felipe Bedoya López
Andrés Felipe Bedoya López
MEMiquel Ensenyat-Mendez
Miquel Ensenyat-Mendez
PAPere Llinàs Arias
Pere Llinàs Arias
SASoo Kyung Ahn
Soo Kyung Ahn
MDMaggie L. DiNome
Maggie L. DiNome
De-escalation of axillary surgery has resulted in the loss of pathologic nodal information, yet the extent of lymph node involvement remains an important determinant of treatment decisions in estrogen receptor-positive (ER+)/HER2− disease. We examined whether primary tumors differed molecularly according to the extent of this regional dissemination. Genome-wide DNA methylation profiling of primary ER+/HER2− tumors from 47 patients with pN1 (n = 29) vs. >pN1 (n = 18) disease showed differences concentrated at promoters of developmental and cell-adhesion genes. By integrating methylomes with transcriptomes from the TCGA-BRCA cohort (n = 148) and clinical outcomes from KM Plotter (RFS, n = 1154; OS, n = 442; DMFS, n = 423), we identified four genes (ARL10, RIC3, CXCL14, KCNH2) showing concordant molecular and clinical associations, from which we derived the Lymph-node Involvement Outcome Numerator (LION) score. Lower LION scores were observed in metastatic lesions from the AURORA US cohort (n = 45). In SCAN-B (n = 3969), lower scores were associated with shorter distant recurrence-free intervals (HR = 0.38; 95% CI 0.23–0.62); this association persisted after adjustment for age, nodal and tumor category but was lost after adjustment for histological grade (HR = 0.83; 95% CI 0.48–1.44), indicating that the score and grade capture overlapping biology. These findings suggest that primary tumors already display coordinated epigenetic and transcriptional alterations associated with the extent of metastatic dissemination.

26 June 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
SISandra Iñiguez-Muñoz
Sandra Iñiguez-Muñoz
ALAndrés Felipe Bedoya López
Andrés Felipe Bedoya López
MEMiquel Ensenyat-Mendez
Miquel Ensenyat-Mendez
PAPere Llinàs Arias
Pere Llinàs Arias
SASoo Kyung Ahn
Soo Kyung Ahn
MDMaggie L. DiNome
Maggie L. DiNome
De-escalation of axillary surgery in breast cancer (BC) reduces surgical morbidity but limits pathological assessment of nodal burden, a key determinant of prognosis and adjuvant therapy in estrogen receptor-positive (ER+)/HER2- BC. Tumor-intrinsic biomarkers that reflect the extent of lymph node disease may help bridge this gap. We performed genome-wide DNA methylation profiling of primary tumors from patients with ER+/HER2- BC stratified by pathological nodal stage (1-3 positive nodes, pN1; 4 or more positive nodes, >pN1). Findings were validated across multiple independent cohorts (TCGA-BRCA, SCAN-B, AURORA US), integrating molecular and clinical data. Forty-seven tumors passed EPIC quality control (pN1: n=29; >pN1: n=18). Tumors with >pN1 disease showed epigenetic reprogramming, including promoter hypermethylation and suppression of genes in pathways related to development and cell adhesion. Across datasets, five genes (TTC23, ARL10, RIC3, CXCL14, KCNH2) were consistently associated with nodal involvement and outcomes. Based on these genes, we developed the LION (Lymph-node Involvement Outcome Numerator) score, which distinguishes tumors with >pN1 disease and is associated with worse distant metastasis-free survival across cohorts. The LION score represents a biologically informed molecular metric associated with nodal involvement in ER+/HER2- BC. These findings provide insight into tumor-intrinsic epigenetic programs linked to dissemination.